EDC Newsletter June 2008
Introducing Applied Clinical Trials' EDC News, a newsletter with news, articles, and information about EDC, IT, and eClinical.
Medidata Raves On EDC
Medidata's Rave EDC product has been moving in some interesting circles. In addition to becoming CDISC compliant, the products' accreditation program has been expanded so that CROs and other partners may achieve graduated levels of Rave service and support. Read about the CDISC initiatives here and about the Certification program here.
Almac Clinical Technologies
Almac Clinical Technologies provides phone and internet based interactive clinical technology solutions that improve the quality and efficiency of the clinical trial process. Our offerings include IVRS/ IXRS, iTrial EDC & ePRO.
www.almacgroup.com
eResearchTechnology
EDC Now! From eRTEDC is Evolving. eRT believes there is a better way.Visit us at DIA Booth# 800 for a demonstration!
invivodata
Clinical trial sponsors talked. We listened. Introducing the SitePRO® Tablet-the right size for site-based ePRO.
Management Forum's The CTD: An Introductory Overview
July 2, 2008
Location | London, UK
Pharmaceutical Information Management 2008
July 14–16, 2008
Location | Philadelphia, PA
CfPIE's FDA Inspections of Clinical Data Systems
July 17–18, 2008
Location | Costa Mesa, CA
Thomas Wells
- appointed OmniComm's vice president of technical operations.
Jim Walker
- of Octagon Research Solutions is a finalist in the American Business Awards.
Alan Gelenberg
- joins Healthcare Technology Systems as president, chief executive officer. (PDF)
Tim Pratt of MedNet Solutions (Minnetonka, MN) offers his comment on for-profit conferences in our industry. Click here to read more.
XClinical, a Germany-based EDC software vendor, participated in the CDISC Interchange in Japan earlier this month. Click here to read more.
Oncology-focused CRO ACORN (Memphis, TN) made its proprietary EDC system available to the clinical trials market. See the company press release here.
You are subscribed to %%list.name%% as %%emailaddr%%. To unsubscribe from this list click here.To ensure delivery to your Inbox, please add %%email.list%% to your address book. If you need help doing this, click here.
Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, simply call (toll free) 1-866-529-2922 at any time, or fax us at 1-218-740-6417. Outside the U.S., please phone 1-218-740-6395. Contact us by mail at Advanstar Communications Inc., 131 West First St., Duluth, MN 55802-2065, USA.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.
